Proteomic identification of differentially expressed proteins associated with the multiple drug resistance in methotrexate-resistant human breast cancer cells

International Journal of Oncology

Volumn 45, Issue 1, 2014, Pages 448-458

  Chen, Siying ^a   Cai, Jiangxia ^a   Zhang, Weipeng ^a   Zheng, Xiaowei ^a   Hu, Sasa ^a   Lu, Jun ^a   Xing, Jianfeng ^a   Dong, Yalin ^a  

^a XI'AN JIAOTONG UNIVERSITY   (China)

Author keywords

Breast cancer; Methotrexate; Molecular targets; Multidrug resistance; Proteomics

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; ALPHA ENOLASE; CISPLATIN; DOCETAXEL; DOXORUBICIN; FLUOROURACIL; GEMCITABINE; HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN; MESSENGER RNA; METHOTREXATE; MITOXANTRONE; NAVELBINE; NUCLEOPHOSMIN; PACLITAXEL; PEMETREXED; PHOSPHOGLYCERATE MUTASE; PROTEASOME; PROTEASOME SUBUNIT ALPHA TYPE 2; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; VIMENTIN; ANTINEOPLASTIC ANTIMETABOLITE;

ARTICLE; CANCER RESISTANCE; CHEMOSENSITIZATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOLOGY; DOWN REGULATION; FLOW CYTOMETRY; GENE EXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; IC 50; MCF 7 CELL LINE; MTT ASSAY; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEOMICS; R FACTOR; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION; BREAST TUMOR; CELL CYCLE; DRUG RESISTANCE; FEMALE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PATHOLOGY;

ANTIMETABOLITES, ANTINEOPLASTIC; BREAST NEOPLASMS; CELL CYCLE; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MCF-7 CELLS; METHOTREXATE; PROTEOMICS;

EID: 84902601222     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2014.2389     Document Type: Article

References (45)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin 61: 69-90, 2011.
2. Bhoo-Pathy N, Yip CH, Hartman M, et al: Breast cancer research in Asia: adopt or adapt Western knowledge? Eur J Cancer 49: 703-709, 2013.
3. Longley DB and Johnston PG: Molecular mechanisms of drug resistance. J Pathol 205: 275-292, 2005.
4. Baguley BC: Multiple drug resistance mechanisms in cancer. Mol Biotechnol 46: 308-316, 2010.
5. Olsen EA: The pharmacology of methotrexate. J Am Acad Dermatol 25: 306-318, 1991.
6. Assaraf YG: Molecular basis of antifolate resistance. Cancer Metastasis Rev 26: 153-181, 2007.
7. de Almagro MC, Selga E, Thibaut R, Porte C, Noe V and Ciudad CJ: UDP-glucuronosyltransferase 1A6 overexpression in breast cancer cells resistant to methotrexate. Biochem Pharmacol 81: 60-70, 2011.
8. Selga E, Morales C, Noe V, Peinado MA and Ciudad CJ: Role of caveolin 1, E-cadherin, Enolase 2 and PKCalpha on resistance to methotrexate in human HT29 colon cancer cells. BMC Med Genomics 1: 35, 2008.
9. Mencia N, Selga E, Noé V and Ciudad CJ: Underexpression of miR-224 in methotrexate resistant human colon cancer cells. Biochem Pharmacol 82: 1572-1582, 2011.
10. Mencia N, Selga E, Rico I, et al: Overexpression of S100A4 in human cancer cell lines resistant to methotrexate. BMC Cancer 10: 250, 2010.
11. Subramanian A and Miller DM: Structural analysis of alpha-enolase. Mapping the functional domains involved in down-regulation of the c-myc protooncogene. J Biol Chem 275: 5958-5965, 2000.
12. Takashima M, Kuramitsu Y, Yokoyama Y, et al: Overexpression of alpha enolase in hepatitis C virus-related hepatocellular carcinoma: association with tumor progression as determined by proteomic analysis. Proteomics 5: 1686-1692, 2005.
13. Chang GC, Liu KJ, Hsieh CL, et al: Identification of alpha-enolase as an autoantigen in lung cancer: its overexpression is associated with clinical outcomes. Clin Cancer Res 12: 5746-5754, 2006.
14. Tsai ST, Chien IH, Shen WH, et al: ENO1, a potential prognostic head and neck cancer marker, promotes transformation partly via chemokine CCL20 induction. Eur J Cancer 46: 1712-1723, 2010.
15. Tu SH, Chang CC, Chen CS, et al: Increased expression of enolase alpha in human breast cancer confers tamoxifen resistance in human breast cancer cells. Breast Cancer Res Treat 121: 539-553, 2010.
16. Chuthapisith S, Layfield R, Kerr ID, Hughes C and Eremin O: Proteomic profiling of MCF-7 breast cancer cells with chemoresistance to different types of anti-cancer drugs. Int J Oncol 30: 1545-1551, 2007.
17. Mizukami Y, Iwamatsu A, Aki T, et al: ERK1/2 regulates intracellular ATP levels through alpha-enolase expression in cardiomyocytes exposed to ischemic hypoxia and reoxygenation. J Biol Chem 279: 50120-50131, 2004.
18. de Sousa Abreu R, Penalva LO, Marcotte EM and Vogel C: Global signatures of protein and mRNA expression levels. Mol Biosyst 5: 1512-1526, 2009.
19. Ivaska J, Pallari HM, Nevo J and Eriksson JE: Novel functions of vimentin in cell adhesion, migration, and signaling. Exp Cell Res 313: 2050-2062, 2007.
20. Singh S, Sadacharan S, Su S, Belldegrun A, Persad S and Singh G: Overexpression of vimentin: role in the invasive phenotype in an androgen-independent model of prostate cancer. Cancer Res 63: 2306-2311, 2003.
21. Karihtala P, Auvinen P, Kauppila S, Haapasaari KM, Jukkola-Vuorinen A and Soini Y: Vimentin, zeb1 and Sip1 are up-regulated in triple-negative and basal-like breast cancers: association with an aggressive tumour phenotype. Breast Cancer Res Treat 138: 81-90, 2013.
22. Tseng YH, Chang KW, Yang CC, et al: Association between areca-stimulated vimentin expression and the progression of head and neck cancers. Head Neck 34: 245-253, 2012.
23. Kim JJ, Yin B, Christudass CS, et al: Acquisition of paclitaxel resistance is associated with a more aggressive and invasive phenotype in prostate cancer. J Cell Biochem 114: 1286-1293, 2013.
24. Sun S, Wong TS, Zhang XQ, et al: Protein alterations associated with temozolomide resistance in subclones of human glioblastoma cell lines. J Neurooncol 107: 89-100, 2012.
25. Liu H, Zhang HW, Sun XF, et al: Tamoxifen-resistant breast cancer cells possess cancer stem-like cell properties. Chin Med J (Engl) 126: 3030-3034, 2013.
26. Krecic AM and Swanson MS: hnRNP complexes: composition, structure, and function. Curr Opin Cell Biol 11: 363-371, 1999.
27. Carpenter B, MacKay C, Alnabulsi A, et al: The roles of heterogeneous nuclear ribonucleoproteins in tumour development and progression. Biochim Biophys Acta 1765: 85-100, 2006.
28. Brockstedt E, Rickers A, Kostka S, et al: Identification of apoptosis-associated proteins in a human Burkitt lymphoma cell line. Cleavage of heterogeneous nuclear ribonucleoprotein A1 by caspase 3. J Biol Chem 273: 28057-28064, 1998.
29. Rahman-Roblick R, Johannes Roblick U, Hellman U, et al: p53 targets identified by protein expression profiling. Proc Natl Acad Sci USA 104: 5401-5406, 2007.
30. Koryllou A, Patrinou-Georgoula M, Troungos C and Pletsa V: Cell death induced by N-methyl-N-nitrosourea, a model SN1 methylating agent, in two lung cancer cell lines of human origin. Apoptosis 14: 1121-1133, 2009.
31. Grover R, Sharathchandra A, Ponnuswamy A, Khan D and Das S: Effect of mutations on the p53 IRES RNA structure: Implications for de-regulation of the synthesis of p53 isoforms. RNA Biol 8: 132-142, 2011.
32. Hossain MN, Fuji M, Miki K, Endoh M and Ayusawa D: Downregulation of hnRNP C1/C2 by siRNA sensitizes HeLa cells to various stresses. Mol Cell Biochem 296: 151-157, 2007.
33. Ren F, Wu H, Lei Y, et al: Quantitative proteomics identification of phosphoglycerate mutase 1 as a novel therapeutic target in hepatocellular carcinoma. Mol Cancer 9: 81, 2010.
34. Evans MJ, Saghatelian A, Sorensen EJ and Cravatt BF: Target discovery in small-molecule cell-based screens by in situ proteome reactivity profiling. Nat Biotechnol 23: 1303-1307, 2005.
35. Gao H, Yu B, Yan Y, et al: Correlation of expression levels of ANXA2, PGAM1, and CALR with glioma grade and prognosis. J Neurosurg 118: 846-853, 2013.
36. Jiang X, Sun Q, Li H, Li K and Ren X: The role of phosphoglycerate mutase 1 in tumor aerobic glycolysis and its potential therapeutic implications. Int J Cancer: Nov 28, 2013 (Epub ahead of print). doi: 10.1002/ijc.28637.
37. Chaneton B and Gottlieb E: PGAMgnam style: a glycolytic switch controls biosynthesis. Cancer Cell 22: 565-566, 2012.
38. Tan JY, Huang X and Luo YL: PSMA7 inhibits the tumorigenicity of A549 human lung adenocarcinoma cells. Mol Cell Biochem 366: 131-137, 2012.
39. Du H, Huang X, Wang S, Wu Y, Xu W and Li M: PSMA7, a potential biomarker of diseases. Protein Pept Lett 16: 486-489, 2009.
40. Sakai A, Otani M, Miyamoto A, Yoshida H, Furuya E and Tanigawa N: Identification of phosphorylated serine-15 and -82 residues of HSPB1 in 5-fluorouracil-resistant colorectal cancer cells by proteomics. J Proteomics 75: 806-818, 2012.
41. Yung BY: Oncogenic role of nucleophosmin/B23. Chang Gung Med J 30: 285-293, 2007.
42. Wong JC, Hasan MR, Rahman M, et al: Nucleophosmin 1, upregulated in adenomas and cancers of the colon, inhibits p53-mediated cellular senescence. Int J Cancer 133: 1567-1577, 2013.
43. Lin M, Hu J, Liu T, Li J, Chen B and Chen X: Knockdown of nucleophosmin by RNA interference reverses multidrug resistance in resistant leukemic HL-60 cells. Immunobiology 218: 1147-1154, 2013.
44. Grisendi S, Mecucci C, Falini B and Pandolfi PP: Nucleophosmin and cancer. Nat Rev Cancer 6: 493-505, 2006.
45. Karhemo PR, Rivinoja A, Lundin J, et al: An extensive tumor array analysis supports tumor suppressive role for nucleophosmin in breast cancer. Am J Pathol 179: 1004-1014, 2011.